Advertisement
BBIO vs DYN
Which Stock Would AI Choose? BridgeBio Pharma (BBIO) vs. Dyne Therapeutics (DYN) Stock Comparison
Key Takeaways
- BridgeBio Pharma (BBIO) holds a significantly larger market capitalization of approximately $14.4 billion compared to Dyne Therapeutics' (DYN) $3 billion, reflecting greater scale and commercial presence.
- BBIO has delivered over 100% one-year returns, outperforming DYN's more volatile path amid biotech sector swings.
- Both companies target rare genetic diseases, but BBIO benefits from commercial revenue via Attruby while DYN advances clinical-stage neuromuscular programs.
- Recent analyst activity favors BBIO with price target hikes to $106, signaling confidence in its pipeline stability over DYN's trial milestones.
- DYN shows higher year-to-date gains at around 8%, driven by Phase 3 trial initiations and conference presentations.
Introduction
BridgeBio Pharma (BBIO) and Dyne Therapeutics (DYN) represent compelling options in the biotechnology sector, both advancing therapies for rare genetic and neuromuscular diseases. This stock comparison evaluates their recent market performance, pipeline progress, and relative positioning amid evolving biotech sentiment. Investors seeking exposure to high-growth clinical and commercial-stage biotechs, particularly those tracking relative performance in genetic disorders, will find insights into momentum, risks, and catalysts shaping these tickers in the current environment.
BBIO Overview and Recent Performance
BridgeBio Pharma (BBIO) is a biopharmaceutical company focused on discovering and delivering medicines for genetic diseases, with key products like Attruby (acoramidis), an oral stabilizer for transthyretin amyloid cardiomyopathy (ATTR-CM), and a late-stage pipeline targeting conditions such as achondroplasia and hypoparathyroidism. In recent market activity, BBIO shares have shown resilience, trading around $74 with a market cap exceeding $14 billion. Performance has been bolstered by commercial progress on Attruby, positive Q4 earnings highlights, and analyst upgrades including price targets raised to $106 by firms like Mizuho. Sentiment has shifted upward due to pipeline advancements and reduced volatility compared to broader biotech peers, with one-year gains surpassing 100%.
DYN Overview and Recent Performance
Dyne Therapeutics (DYN) specializes in neuromuscular diseases using its proprietary FORCE platform to deliver oligonucleotides for conditions like myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD), and others. Shares recently hovered near $18, with a market cap of about $3 billion. In recent weeks, DYN has gained traction from preclinical data presentations at conferences like ASGCT, initiation of the Phase 3 HARMONIA trial for DM1, and participation in managed care events. Year-to-date returns stand positive around 8%, though higher beta reflects volatility tied to clinical milestones and biotech sector dynamics.
Trending AI Robots
Tickeron’s Trending AI Robots page showcases the platform's top-performing AI trading bots, curated from hundreds available—specifically 25 selected out of 351 total bots—for current market conditions. These AI agents deliver real-time signals across stocks, ETFs, and crypto, employing diverse strategies such as swing trading, scalping, and long-term holds, with varying timeframes from intraday to multi-week. Each bot trades distinct sets of tickers based on its model, offering win rates, profit factors, and return profiles tailored to volatility and trends. Traders can explore these high-conviction options to enhance decision-making; visit the page to review and potentially copy top performers.
Head-to-Head Comparison
BridgeBio Pharma (BBIO) and Dyne Therapeutics (DYN) operate in the biotech space but diverge in business models: BBIO blends commercial revenue from approved therapies like Attruby with a broad genetic disease pipeline, providing cash flow stability, while DYN remains pre-commercial, relying on its FORCE platform for neuromuscular-focused clinical advancement. Growth drivers contrast sharply—BBIO leverages existing sales and late-stage readouts versus DYN's high-potential Phase 3 trials. Recent momentum favors BBIO's steady climb amid analyst support, though DYN exhibits sharper upside on trial news. Risk profiles show both with betas above 1.0 (BBIO at 1.09, DYN at 1.28), but BBIO's scale mitigates execution risks. Sector exposure aligns in rare diseases, yet market sentiment tilts toward BBIO's proven traction.
Tickeron AI Verdict
Tickeron’s AI currently leans toward BridgeBio Pharma (BBIO) based on superior trend consistency, commercial stability, and relative market positioning versus DYN's higher clinical risk. Observable factors like sustained price strength, analyst conviction, and revenue generation suggest a probabilistic edge for BBIO in the near term, though DYN could outperform on positive trial catalysts.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer. Disclaimers and Limitations
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BBIO is a Buy and DYN is a Buy.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BBIO’s FA Score shows that 1 FA rating(s) are green whileDYN’s FA Score has 1 green FA rating(s).
- BBIO’s FA Score: 1 green, 4 red.
- DYN’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BBIO’s TA Score shows that 3 TA indicator(s) are bullish while DYN’s TA Score has 6 bullish TA indicator(s).
- BBIO’s TA Score: 3 bullish, 3 bearish.
- DYN’s TA Score: 6 bullish, 3 bearish.
Price Growth
BBIO (@Biotechnology) experienced а +1.32% price change this week, while DYN (@Biotechnology) price change was +11.53% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +7.11%. For the same industry, the average monthly price growth was +3.26%, and the average quarterly price growth was +1969.89%.
Reported Earning Dates
BBIO is expected to report earnings on Jul 30, 2026.
DYN is expected to report earnings on Jul 30, 2026.
Industries' Descriptions
@Biotechnology (+7.11% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
| BBIO | DYN | BBIO / DYN | |
| Capitalization | 13.5B | 3.45B | 391% |
| EBITDA | -535.2M | -439.22M | 122% |
| Gain YTD | -9.923 | 6.800 | -146% |
| P/E Ratio | N/A | N/A | - |
| Revenue | 580M | 0 | - |
| Total Cash | 940M | 972M | 97% |
| Total Debt | 2.49B | 169M | 1,475% |
BBIO | ||
|---|---|---|
OUTLOOK RATING 1..100 | 7 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 3 Undervalued | |
PROFIT vs RISK RATING 1..100 | 85 | |
SMR RATING 1..100 | 100 | |
PRICE GROWTH RATING 1..100 | 51 | |
P/E GROWTH RATING 1..100 | 100 | |
SEASONALITY SCORE 1..100 | 12 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BBIO | DYN | |
|---|---|---|
| RSI ODDS (%) | N/A | N/A |
| Stochastic ODDS (%) | 2 days ago 85% | 2 days ago 86% |
| Momentum ODDS (%) | 2 days ago 82% | 2 days ago 81% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 80% |
| TrendWeek ODDS (%) | 2 days ago 80% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 85% | 2 days ago 85% |
| Advances ODDS (%) | 19 days ago 80% | 2 days ago 83% |
| Declines ODDS (%) | 22 days ago 80% | 16 days ago 86% |
| BollingerBands ODDS (%) | N/A | 2 days ago 84% |
| Aroon ODDS (%) | 2 days ago 83% | 2 days ago 90% |
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| SOXY | 114.39 | 1.99 | +1.77% |
| YieldMax Target 12 Smcndctr Opt Inc ETF | |||
| MNZL | 61.07 | 0.25 | +0.42% |
| Manzil Russell Halal USA Broad MarketETF | |||
| KOCT | 37.13 | 0.10 | +0.26% |
| Innovator US Small Cap Pwr Buff ETF™ Oct | |||
| SUSA | 153.14 | -0.11 | -0.07% |
| iShares ESG Optimized MSCI USA ETF | |||
| NBOS | 28.10 | -0.03 | -0.11% |
| Neuberger Option Strategy ETF | |||
BBIO and
Correlation & Price change
A.I.dvisor indicates that over the last year, BBIO has been loosely correlated with AXON. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if BBIO jumps, then AXON could also see price increases.
| Ticker / NAME | Correlation To BBIO | 1D Price Change % | ||
|---|---|---|---|---|
| BBIO | 100% | +3.97% | ||
| AXON - BBIO | 44% Loosely correlated | -3.16% | ||
| ARRY - BBIO | 43% Loosely correlated | +6.75% | ||
| PMN - BBIO | 43% Loosely correlated | +1.28% | ||
| KURA - BBIO | 41% Loosely correlated | +4.33% | ||
| DYN - BBIO | 39% Loosely correlated | +5.51% | ||
More | ||||
DYN and
Correlation & Price change
A.I.dvisor indicates that over the last year, DYN has been loosely correlated with RNA. These tickers have moved in lockstep 64% of the time. This A.I.-generated data suggests there is some statistical probability that if DYN jumps, then RNA could also see price increases.
| Ticker / NAME | Correlation To DYN | 1D Price Change % | ||
|---|---|---|---|---|
| DYN | 100% | +5.51% | ||
| RNA - DYN | 64% Loosely correlated | +2.21% | ||
| RCUS - DYN | 46% Loosely correlated | +12.01% | ||
| VYGR - DYN | 45% Loosely correlated | N/A | ||
| XNCR - DYN | 44% Loosely correlated | +10.84% | ||
| NTLA - DYN | 44% Loosely correlated | +0.51% | ||
More | ||||